Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. (Q53178120)
Jump to navigation
Jump to search
scientific article published on 5 July 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. |
scientific article published on 5 July 2017 |
Statements
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. (English)
1 reference
Jhanelle E Gray
1 reference
Rebecca S Heist
1 reference
Alexander N Starodub
1 reference
D Ross Camidge
1 reference
Ebenezer A Kio
1 reference
Gregory A Masters
1 reference
W Thomas Purcell
1 reference
Michael J Guarino
1 reference
Jamal Misleh
1 reference
Charles J Schneider
1 reference
Bryan J Schneider
1 reference
Allyson Ocean
1 reference
Tirrell Johnson
1 reference
Leena Gandhi
1 reference
Kevin Kalinsky
1 reference
Ronald Scheff
1 reference
Wells A Messersmith
1 reference
Serengulam V Govindan
1 reference
Pius P Maliakal
1 reference
Boyd Mudenda
1 reference
William A Wegener
1 reference
Robert M Sharkey
1 reference
David M Goldenberg
1 reference
5 July 2017
1 reference
23
1 reference
5711-5719
1 reference
19
1 reference
Identifiers
1 reference